PBYI - Puma Bio reports data from mid-stage study of neratinib in EGFR exon 18-mutant NSCLC patients

Puma Biotechnology (PBYI) presents interim results from the Phase II SUMMIT basket trial, assessing the efficacy of neratinib in patients with EGFR exon 18-mutant non-small cell lung cancer ((NSCLC)), including patients with central nervous system ((CNS)) involvement, at the virtual 2021 ASCO Annual Meeting. Of the 10 evaluable patients who had previously been treated with an EGFR tyrosine kinase inhibitor, 6 patients (60%) experienced a partial response ((PR)), and 4 (40%) demonstrated a confirmed PR.Four additional patients showed stable disease ((SD)) lasting ?16 weeks – bringing the experienced clinical benefit to 80%.The median duration of response was 7.5 months, and the median progression-free survival ((PFS)) was 9.1 months with some patients remaining on treatment.Of the 3 patients who had CNS metastases, best responses were 2 PR and 1 SD and individual PFS times were 1.9 to 9.1 months.These results suggest that neratinib can be a potential treatment option for patients

For further details see:

Puma Bio reports data from mid-stage study of neratinib in EGFR exon 18-mutant NSCLC patients